Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Maitland, Florida

CNS medication trials in Maitland, FL

26 CNS medication studies are recruiting participants at sites in Maitland as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Maitland at a glance

Depression studies recruiting in Maitland

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    Accel Research Sites - Maitland
    Registry record
    NCT06793397 · updated
  2. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    K2 Medical Research (Maitland)
    Registry record
    NCT07592689 · updated
  3. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    K2 Medical Research - Maitland
    Registry record
    NCT07412756 · updated
  4. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    K2 Medical Research
    Registry record
    NCT07573176 · updated
  5. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06966401 · updated
  6. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tonix Pharmaceuticals, Inc.
    Registry record
    NCT07621237 · updated
  7. NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06963021 · updated
  8. Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06786624 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Maitland, FL on ClinicalTrials.gov.

Schizophrenia studies recruiting in Maitland

  1. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    K2 Medical Research
    Registry record
    NCT06540833 · updated
  2. A Study of Brenipatide in Adult Participants With Schizophrenia

    • Phase 2
    • Ages 18 to 55
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Accel Research Sites - Maitland Clinical Research Unit
    Registry record
    NCT07410507 · updated
  3. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT07114874 · updated
  4. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT07227818 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Maitland, FL on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Maitland

  1. A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study sites
    Accel Research Sites - Maitland Clinical Research Unit · K2 Medical Research - Maitland
    Registry record
    NCT07286175 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Maitland, FL on ClinicalTrials.gov.

ADHD studies recruiting in Maitland

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717879 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717892 · updated
  3. A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Otsuka Pharmaceutical Development & Commercialization, Inc.
    Study site
    Accel Research Sites-Maitland
    Registry record
    NCT07759154 · updated
  4. A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Alkermes, Inc.
    Study sites
    Alkermes Investigational Site · Alkermes Investigator Site
    Registry record
    NCT07755410 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Maitland, FL on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Maitland

  1. SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

    • Phase 1
    • Ages 40 to 80
    • All sexes
    Sponsor
    Serina Therapeutics
    Study site
    K2 Medical Research LLC
    Registry record
    NCT07422675 · updated
  2. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    K2 Medical Research-Maitland
    Registry record
    NCT07174310 · updated
  3. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    • Phase 2/3
    • Ages 40 to 80
    • All sexes
    Sponsor
    Biohaven Therapeutics Ltd.
    Registry record
    NCT06976268 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Maitland, FL on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Maitland

  1. A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Zenas BioPharma (USA), LLC
    Study site
    Neurology Associates
    Registry record
    NCT07299019 · updated
  2. A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Zenas BioPharma (USA), LLC
    Study site
    Neurology Associates, PA
    Registry record
    NCT07067463 · updated
  3. A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Genentech, Inc.
    Study site
    Neurology Associates, PA
    Registry record
    NCT07609719 · updated
  4. Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    • Phase 3
    • Ages 40 to 70
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Neurology Associates PA
    Registry record
    NCT06846281 · updated
  5. A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Neurology Associates PA
    Registry record
    NCT07225504 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Maitland, FL on ClinicalTrials.gov.

Epilepsy studies recruiting in Maitland

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Registry record
    NCT07594119 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Maitland, FL on ClinicalTrials.gov.

Ask about studies near Maitland

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call